Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Anavex Lf SC (NQ: AVXL)
2.750 USD  +0.040 (+1.48%)
Official Closing Price  /  Updated: 4:59 PM EDT, Aug 19, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 216,037
Open 2.740
Bid (Size) 2.610 (1)
Ask (Size) 2.810 (10)
Prev. Close 2.710
Today's Range 2.610 - 2.826
52wk Range 1.250 - 4.090
Shares Outstanding 44,660,062
Dividend Yield N/A
Performance
YTD
+63.69%
+63.69%
1 Month
+8.27%
+8.27%
3 Month
-19.59%
-19.59%
6 Month
+14.58%
+14.58%
1 Year
+3.38%
+3.38%
Top News
More News
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates
Conference Call and Webcast Today at 4:30 p.m. ET Read More
from GlobeNewswire News Releases
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019
Conference Call and Webcast To be Held Wednesday, August 7, 2019 4:30 p.m. Eastern Time Read More
from GlobeNewswire News Releases
More News
Read More
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome
from GlobeNewswire News Releases
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome
from GlobeNewswire News Releases
Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer’s Association In
from GlobeNewswire News Releases
Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome
from GlobeNewswire News Releases
Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome (AVATAR)
from GlobeNewswire News Releases
Look Under The Hood: SPSM Has 21% Upside
category ETFs
from ETF Channel
First Week of September 20th Options Trading For Anavex Life Sciences (AVXL)
category Stocks
from Market News Video
Friday Sector Laggards: Biotechnology, REITs
category Stocks
from Market News Video
We Did The Math SPTM Can Go To $40
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.